阿
ATR
阿普達
126.01
-0.74-0.58%After Hours: 126.01 0.00 0.00%16:11 04/02 EDT
OPEN/PREV CLOSE125.14/126.75
TODAY RANGE124.25-127.09
VOL297.47K
MARKET CAP8.04B
52 WEEK RANGE102.83-163.04
AVG VOL (3M)528.46K
% TURNOVER0.47%
TURNOVER--
P/E (TTM)21.41
% RANGE2.24%
EPS(TTM)5.89
P/E(FORWARD)23.12
P/B3.032
BVPS41.56
DIVIDEND1.920
P/S2.142
BETA--
DIV YIELD1.52%
FREE FLOAT MKT CAP8.01B
SHARES OUTSTANDING63.77M
NEXT EARNINGS02/04-02/09
FREE FLOAT63.60M
LOT SIZE1
EX-DATE02/04/2026
News
Press Releases
Financial Reports
Profile
Simply Wall St·3d ago
How Investors May Respond To AptarGroup (ATR) Powering ENA’s Phase II Intranasal Antiviral Study
Simply Wall St·03/27 18:10
Assessing AptarGroup (ATR) Valuation After Recent Share Price Weakness
NASDAQ·03/26 09:43
New Strong Sell Stocks for March 26th
Simply Wall St·03/25 03:17
Did CEO Succession and Nasal Drug Collaborations Just Shift AptarGroup's (ATR) Investment Narrative?
Simply Wall St·03/22 06:04
AptarGroup’s Nasal Devices Gain Ground In Respiratory Trials And Leadership Shift
Benzinga·03/20 14:06
Wells Fargo Upgrades AptarGroup to Overweight, Raises Price Target to $144
Dow Jones·03/20 14:01
AptarGroup Price Target Raised to $144.00/Share From $133.00 by Wells Fargo
Dow Jones·03/20 14:01
AptarGroup Raised to Overweight From Equal-Weight by Wells Fargo
NASDAQ·03/20 09:09
New Strong Sell Stocks for March 20th
TipRanks·03/19 21:05
AptarGroup’s unidose powder nasal delivery system used in ENA Phase 2 study
TipRanks·03/19 12:05
DBS Sticks to Its Buy Rating for AptarGroup (ATR)
Benzinga·03/18 14:16
AptarGroup Hires New CEO
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.